Publisher, "Chronic Rhinosinustis - Pipeline Insight, 2021," report provides comprehensive insights about 2+ companies and 3+ pipeline drugs in Chronic Rhinosinustis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Chronic Rhinosinustis Understanding
Chronic Rhinosinustis: Overview
Rhinosinusitis is defined as inflammation of the mucosal linings of the nasal passage and paranasal sinuses. Chronic rhinosinusitis occurs when symptoms lasts longer than 12 weeks. The symptoms of chronic rhinosinusitis include nasal inflammation, facial pain/pressure, hyposmia/anosmia, nasal congestion, loss of sense of smell and sleep difficulties, and discolored nasal drainage. Chronic rhinosinusitis is diagnosed clinically with a physical examination and focused sinonasal history, including chronic rhinosinusitis, associated comorbidities and family history. The treatment for chronic rhinosinusitis is focused at enhancing mucociliary clearance, improving sinus drainage/outflow, eradicating local infection and inflammation, and improving access for topical medications. First-line treatment is nasal saline irrigation and intranasal corticosteroid sprays.
"Chronic Rhinosinustis - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Rhinosinustis pipeline landscape is provided which includes the disease overview and Chronic Rhinosinustis treatment guidelines. The assessment part of the report embraces, in depth Chronic Rhinosinustis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Rhinosinustis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Rhinosinustis R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Rhinosinustis.
Chronic Rhinosinustis Emerging Drugs Chapters
This segment of the Chronic Rhinosinustis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Rhinosinustis Emerging Drugs
- LYR-210: Lyra Therapeutics
LYR-210 is a glucocorticoid receptor agonist. It is an anti-inflammatory implantable drug matrix based on Lyra's XTreo platform that is designed to consistently and locally elute mometasone furoate to the inflamed mucosal tissue for up to six months in surgically-naive chronic rhinosinusitis patients who fail medical management. The drug is in Phase II clinical development for the treatment of chronic rhinosinusitis.
Further product details are provided in the report..
Chronic Rhinosinustis: Therapeutic Assessment
This segment of the report provides insights about the different Chronic Rhinosinustis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Chronic Rhinosinustis
There are approx. 2+ key companies which are developing the therapies for Chronic Rhinosinustis. The companies which have their Chronic Rhinosinustis drug candidates in the most advanced stage, i.e. Phase II include, Lyra Therapeutics.
- Phases
Publisher report covers around 3+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Chronic Rhinosinustis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Chronic Rhinosinustis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Chronic Rhinosinustis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Rhinosinustis drugs.
Chronic Rhinosinustis Report Insights
- Chronic Rhinosinustis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Chronic Rhinosinustis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chronic Rhinosinustis drugs-
- How many Chronic Rhinosinustis drugs are developed by each company-
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Rhinosinustis-
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Rhinosinustis therapeutics-
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies-
- What are the clinical studies going on for Chronic Rhinosinustis and their status-
- What are the key designations that have been granted to the emerging drugs-
Key Players
- Lyra Therapeutics
- Gossamer Bio
Key Products
- LYR-210
- LYR-220
- GB001
Table of Contents
Introduction
Executive Summary
Chronic Rhinosinustis: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Chronic Rhinosinustis - Publisher Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
- Comparative Analysis
LYR-210: Lyra Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Drug profiles in the detailed report..
Preclinical/Discovery Stage Products
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Drug profiles in the detailed report..
Inactive Products
- Comparative Analysis
Chronic Rhinosinustis Key Companies
Chronic Rhinosinustis Key Products
Chronic Rhinosinustis- Unmet Needs
Chronic Rhinosinustis- Market Drivers and Barriers
Appendix
List of Tables
Table 1 Total Products for Chronic Rhinosinustis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Chronic Rhinosinustis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
- Lyra Therapeutics
- Gossamer Bio
Global Freckle-removing Medical and Beau..
The global market for Freckle-removing Medical and Beauty Eq..
+16467917070US (Toll Free)